Navigation Links
Investigational Cancer Drug Pertuzumab Shows Promising Results in,Advanced Breast Cancer When Combined with Herceptin

Investigational cancer drug Pertuzumab shows promising results in advanced breast cancer when combined with Herceptin Phase III development initiated

BASEL, Switzerland, June 4, 2007-Early clinical results from Roche's trial of the exciting new cancer medicine pertuzumab, a HER dimerisation inhibitor, show substantial anti-tumour activity in patients with pre-treated HER2 positive breast cancer, when combined with Herceptin. The study showed that one in five patients responded to pertuzumab treatment and one in five also had stabilization of their disease lasting 6 months or more. The results are particularly promising, as the benefits were seen in patients with late stage cancer, whose options for further treatment are limited.

"This is potentially good news for patients whose HER2 positive breast cancer is not responding to current treatments," commented Dr Jose Baselga, lead investigator, Vall d'Hebron University Hospital, Barcelona, Spain. "We are encouraged by the initial results from this trial and are continuing to further recruit patients into the second stage of the study."

The phase II study presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, investigated the combination of two of Roche's HER2 targeted agents, pertuzumab and Herceptin, in patients with HER2 positive metastatic breast cancer whose disease had progressed during treatment with Herceptin plus chemotherapy (1).

Pertuzumab is the first in a new innovative class of targeted agents known as HER dimerization inhibitors (HDIs). The drug inhibits the 'pairing' or dimerization of the protein HER2 with other HER family receptors (HER1, HER2, HER3, and HER4). This interaction is believed to play an important role in the growth and formation of several different cancer types. Pertuzumab in combination adds to the activity of Herceptin due to its different mode of action. "The positive results f
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
3. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
4. Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
5. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
6. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
7. Investigational Drug Cediranib (AZD2171) Shows Promise in Patients With Recurrent Glioblastoma (GBM)
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
9. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
10. Shire Announces Positive Results of Studies With Guanfacine Extended Release, An Investigational Nonstimulant Medication Filed for the Treatment of ADHD in Children and Adolescents
11. Investigational Study Evaluates the Effectiveness of Aripiprazole in Adolescents With Schizophrenia
Post Your Comments:
(Date:10/22/2014)... and SHANGHAI , Oct. 22, ... FMI ) and WuXi PharmaTech (Cayman) Inc. ... to offer Foundation Medicine,s comprehensive genomic profiling to biopharmaceutical ... . Under the terms of the ... perform the laboratory component of Foundation Medicine,s FoundationOne® assay ...
(Date:10/20/2014)... ENGLEWOOD, Colo. , Oct. 20, 2014 /PRNewswire/ ... Inc. (NYSE MKT: AMPE), today announced that its ... the clinical and research potential for its novel ... oxidation-reduction potential (ORP) in the body in response ... clinical value of ORP as a clinical marker ...
(Date:10/20/2014)...  AnaptysBio, Inc., a leader in the discovery ... appointment of Marco Londei , M.D. as ... preclinical and clinical development of AnaptysBio,s proprietary antibody ... welcome Dr. Londei to AnaptysBio,s executive leadership team," ... Executive Officer of AnaptysBio. "Dr. Londei,s extensive expertise ...
Breaking Medicine Technology:Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 2Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 3Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 4Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 5Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 2Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 3Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 4Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 5AnaptysBio Appoints Dr. Marco Londei to Newly Created Chief Development Officer Position Clinical Immunologist to Lead AnaptysBio's Pipeline Advancement 2
... 24, 2011 Reportlinker.com announces ... report is available in its ... Devices Market in Emerging Economies ... Investments in Hospitals to be ...
... 2011 Reportlinker.com announces that a ... in its catalogue: ... Americas Market to 2016 - Growth ... the Pharmaceutical Patent Cliff will Shape ...
Cached Medicine Technology:Endoscopy Devices Market in Emerging Economies (India, China, Brazil) - Growing Investments in Hospitals to be the Major Growth Driver 2Endoscopy Devices Market in Emerging Economies (India, China, Brazil) - Growing Investments in Hospitals to be the Major Growth Driver 3Endoscopy Devices Market in Emerging Economies (India, China, Brazil) - Growing Investments in Hospitals to be the Major Growth Driver 4Endoscopy Devices Market in Emerging Economies (India, China, Brazil) - Growing Investments in Hospitals to be the Major Growth Driver 5Endoscopy Devices Market in Emerging Economies (India, China, Brazil) - Growing Investments in Hospitals to be the Major Growth Driver 6Endoscopy Devices Market in Emerging Economies (India, China, Brazil) - Growing Investments in Hospitals to be the Major Growth Driver 7Active Pharmaceutical Ingredients (APIs) in the Americas Market to 2016 - Growth in Biotechnology and Generic Segments and the Pharmaceutical Patent Cliff will Shape the Landscape 2Active Pharmaceutical Ingredients (APIs) in the Americas Market to 2016 - Growth in Biotechnology and Generic Segments and the Pharmaceutical Patent Cliff will Shape the Landscape 3Active Pharmaceutical Ingredients (APIs) in the Americas Market to 2016 - Growth in Biotechnology and Generic Segments and the Pharmaceutical Patent Cliff will Shape the Landscape 4Active Pharmaceutical Ingredients (APIs) in the Americas Market to 2016 - Growth in Biotechnology and Generic Segments and the Pharmaceutical Patent Cliff will Shape the Landscape 5Active Pharmaceutical Ingredients (APIs) in the Americas Market to 2016 - Growth in Biotechnology and Generic Segments and the Pharmaceutical Patent Cliff will Shape the Landscape 6Active Pharmaceutical Ingredients (APIs) in the Americas Market to 2016 - Growth in Biotechnology and Generic Segments and the Pharmaceutical Patent Cliff will Shape the Landscape 7Active Pharmaceutical Ingredients (APIs) in the Americas Market to 2016 - Growth in Biotechnology and Generic Segments and the Pharmaceutical Patent Cliff will Shape the Landscape 8Active Pharmaceutical Ingredients (APIs) in the Americas Market to 2016 - Growth in Biotechnology and Generic Segments and the Pharmaceutical Patent Cliff will Shape the Landscape 9Active Pharmaceutical Ingredients (APIs) in the Americas Market to 2016 - Growth in Biotechnology and Generic Segments and the Pharmaceutical Patent Cliff will Shape the Landscape 10Active Pharmaceutical Ingredients (APIs) in the Americas Market to 2016 - Growth in Biotechnology and Generic Segments and the Pharmaceutical Patent Cliff will Shape the Landscape 11Active Pharmaceutical Ingredients (APIs) in the Americas Market to 2016 - Growth in Biotechnology and Generic Segments and the Pharmaceutical Patent Cliff will Shape the Landscape 12
(Date:10/22/2014)... 2014 Lintelus, Inc., an event software ... of Sales, will be speaking on the subject of ... on October 28, at the Holiday Inn in New ... as well as a Tech Demo at 12:45pm, to ... a more engaging event experience. , The Annual Meetings ...
(Date:10/22/2014)... 22, 2014 Akeso Biomedical, Inc. ... the treatment of bacterial infections, microbial biofilms, and chronic ... its board of directors. , Dr. Sinskey ... at The Massachusetts Institute of Technology, or MIT. He ... 1968. Dr. Sinskey also holds positions as Co-Director of ...
(Date:10/22/2014)... Maureen Salamon HealthDay ... Black women undergoing in vitro fertilization (IVF) are only about ... the popular assisted reproduction technique, new research indicates, and the ... In the study, about 31 percent of white patients became ... patients. Analyzing more than 4,000 IVF cycles over two ...
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. 21, ... may lead to increased blood pressure, according to a new ... in blood pressure for young adult women or for teenagers, ... drank lightly or moderately, their risk of high blood pressure ... parallels studies in older adult men and women," said lead ...
(Date:10/22/2014)... taken by Firestone officials at the company,s rubber ... spread of the disease there and could prove effective ... provides health services to about 80,000 employees, retirees, their ... Between Aug. 1 and Sept. 23, there were 71 ... That incidence rate of 0.09 percent was much lower ...
Breaking Medicine News(10 mins):Health News:Jay Cormier, Sr. Vice President of Sales for Lintelus, Speaks about Event Technology Integration at Meetings Technology Expo in NYC 2Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 3Health News:Binge Drinking May Boost Blood Pressure in Young Men 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 3Health News:Binge Drinking May Boost Blood Pressure in Young Men 4Health News:Tire Company Sets Standard for Ebola Care in Liberia: CDC 2
... ... Berkeley Heights campus. , ... January 15, 2010 -- Kanan Shridharani, MD, has recently joined Summit Medical Group’s Internal Medicine ... University , New York, NY in 1986. She went on to earn her MD in ...
... may stave off eye disease, research suggests, , FRIDAY, Jan. ... many calories and too much sodium increase their risk for ... 469 black participants who had type 1 diabetes. Six years ... and had photos taken of their eyes to determine the ...
... , PALM DESERT, Calif. , ... superstar Katy Perry has signed on to appear ... experience fighting acne and finding Proactiv® Solution .  Katy ... exciting new 2010 campaign which will introduce new technology and ...
... a common gastrointestinal functional disorder that can greatly ... including alterations in the intestinal microbiota, are suspected ... article to be published on December 21, 2009 ... addresses this question. The research team from Finland ...
... It is reasonable to obtain a histological diagnosis before ... or unwilling to undergo surgery. As the pancreas is ... it is a challenge for the physician to obtain ... of pancreatic masses has been proved to be a ...
... the most common chronic disease of the world and ... Taiwan. Gastroparesis is reported in 5% to 12% of ... uncommon disease resulting compression of the third portion of ... syndrome can cause the same symptoms as diabetic gastroparesis. ...
Cached Medicine News:Health News:Summit Medical Group Welcomes Kanan Shridharani, M.D. 2Health News:Blacks With Diabetes Urged to Cut Calories, Salt 2Health News:Singer-Songwriter Katy Perry Signs On to Tell Proactiv(R) Story 2Health News:Singer-Songwriter Katy Perry Signs On to Tell Proactiv(R) Story 3Health News:Singer-Songwriter Katy Perry Signs On to Tell Proactiv(R) Story 4
... purified non-ionic fraction of agar. Forms gel ... concentrations. Can be mounted on microscope slides ... elastic and durable and show little or ... or lipoprotein dyes. Contaminants: ash: ...
... Certified PCR agarose is recommended for separations ... agarose forms gels that are easy to ... gel percentages, which minimizes the risk of ... genetic quality tested (GQT) products with similar ...
... Agarose-HR™ High Resolution - ... from 50 to 1000 ... for sizing PCR fragments, ... by restriction enzyme digestion, ...
The reading of agglutinations process in Diana Reader is by image treatment which allows great sensitivity....
Medicine Products: